Multiple SclerosisNCT07415824
Multiple Sclerosis Implementation Network (Registry)
An observational study of Multiple Sclerosis, run by The University of Texas Health Science Center, Houston at 3 sites in United States.
Trial summary
The Multiple Sclerosis Implementation Network (MSIN) is a collaboration between the Multiple Sclerosis Association of America (MSAA), The University of Texas Health Science Center at Houston (UTHealth Houston), Dell Medical School at The University of Texas at Austin, and Novartis Pharmaceuticals Corporation. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multiple Sclerosis
- How many people
- 2,000 participants
- Where
- 3 sitesUnited States
- Study dates
- 28 Apr 2025to 31 Dec 2030
- How long will I take part?
- 2 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Clinics in the United States treating MS patients.
Who may be able to join
- diagnosed with Multiple Sclerosis
- can speak and understand English comfortably
Who cannot join
None listed.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States3 sites, 3 recruiting
- Recruiting
The University of Texas at Austin
Austin, Texas, 78712
Leorah Freeman, MD, PhD, (713) 992-9213, Leorah.Freeman@austin.utexas.edu
- Recruiting
Multiple Sclerosis Association of America
Cherry Hill, New Jersey, 08034
Amanda Mantague, Ed.M., 800-532-7667, AMontague@MYMSAA.org
- Recruiting
The University of Texas Health Science Center at Houston (UTHealth Houston)
Houston, Texas, 77030
Maria E. Fernandez, PhD, (713) 500-9626, Maria.E.Fernandez@uth.tmc.edu
About this study
Official title: Multiple Sclerosis Implementation Network
The Multiple Sclerosis Implementation Network (MSIN) is a collaboration between the Multiple Sclerosis Association of America (MSAA), The University of Texas Health Science Center at Houston (UTHealth Houston), Dell Medical School at The University of Texas at Austin, and Novartis Pharmaceuticals Corporation. The goal of MSIN is to improve Multiple Sclerosis (MS) care, patient health, and quality of life through the development and support of implementation research and clinical practice collaboration. MSIN brings together healthcare teams, people with MS, and research leaders in MS and implementation science (IS) to learn, share, test, implement, and disseminate innovations that improve MS care, patient health, and quality of life.
This ClinicalTrials.gov record pertains to the MSIN Patient Registry, which is a comprehensive database that integrates participants' electronic health records from various providers.
- Conditions
- Multiple Sclerosis
- Medical subject headings
- Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with Multiple Sclerosis | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Multiple sclerosis disability as assessed by the Patient-Determined Disease Steps (PDDS) Scale
Total score on the PDDS ranges from 0 (normal) to 8 (Bedridden: Unable to sit in a wheelchair for more than one hour), with a higher score indicating a worse outcome.
Measured: 5 years
Perception of cognitive impairment as assessed by the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) Scale
Total score on the MSNQ ranges from 0 to 60, with a higher score indicating greater perceived cognitive impairment.
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2026
- Study start28 Apr 2025
- Primary completion31 Dec 2030 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- More trials run by The University of Texas Health Science Center, HoustonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 2,000 participants (estimated)
- Target duration
- 2 Years
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- Novartis, Multiple Sclerosis Association of America, The University of Texas at Austin
- Responsible party
- Principal investigator, Maria E Fernandez, The University of Texas Health Science Center, Houston
- Investigators
- Amanda Montague, EdM, Study director, Multiple Sclerosis Association of America
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07415824
- Sponsor's protocol ID
- HSC-SPH-24-0515 (Registry)
- Status last verified
- Jan 2026
- First submitted
- 29 Jan 2026
- Last updated
- 17 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multiple Sclerosis Implementation Network
- ClinicalTrials.gov ID
- NCT07415824
- Acronym / sponsor ID
- HSC-SPH-24-0515 (Registry)
- Conditions
- Multiple Sclerosis
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- The University of Texas Health Science Center, HoustonUniversity, hospital or other
- Collaborators
- Novartis, Multiple Sclerosis Association of America, The University of Texas at Austin
- Study start
- 28 Apr 2025 (actual)
- Primary completion
- 31 Dec 2030 (estimated)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 17 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Multiple Sclerosis Implementation Network (MSIN) is a collaboration between the Multiple Sclerosis Association of America (MSAA), The University of Texas Health Science Center at Houston (UTHealth Houston), Dell Medical School at The University of Texas at Austin, and Novartis Pharmaceuticals Corporation. The goal of MSIN is to improve Multiple Sclerosis (MS) care, patient health, and quality of life through the development and support of implementation research and clinical practice collaboration. MSIN brings together healthcare teams, people with MS, and research leaders in MS and implementation science (IS) to learn, share, test, implement, and disseminate innovations that improve MS care, patient health, and quality of life.
This ClinicalTrials.gov record pertains to the MSIN Patient Registry, which is a comprehensive database that integrates participants' electronic health records from various providers.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 2 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with Multiple Sclerosis | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Clinics in the United States treating MS patients.
Key inclusion criteria (2 listed)
- diagnosed with Multiple Sclerosis
- can speak and understand English comfortably
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Multiple sclerosis disability as assessed by the Patient-Determined Disease Steps (PDDS) Scale
Time frame: 5 years
Total score on the PDDS ranges from 0 (normal) to 8 (Bedridden: Unable to sit in a wheelchair for more than one hour), with a higher score indicating a worse outcome.
Perception of cognitive impairment as assessed by the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) Scale
Time frame: 5 years
Total score on the MSNQ ranges from 0 to 60, with a higher score indicating greater perceived cognitive impairment.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Multiple Sclerosis
Recruiting
Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity
Multiple Sclerosis (MS) - Relapsing-remitting
Recruiting
Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study
Multiple Sclerosis (MS) - Relapsing-remitting, Upper Extremity Dysfunction
Recruiting
Motor Learning in Health and Movement Disorders: Role of Physical Activity and Advanced Devices
Healthy Individuals (Controls), Parkinson Disease
RecruitingPhase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Multiple Sclerosis (MS) Primary Progressive
Active, not recruiting
MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Amanda Montague, EdM study director
Multiple Sclerosis Association of America
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Multiple Sclerosis, run by The University of Texas Health Science Center, Houston at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Amanda Montague, EdM (800-532-7667, AMontague@MYMSAA.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Multiple sclerosis disability as assessed by the Patient-Determined Disease Steps (PDDS) Scale (time frame: 5 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2026.